Skip to main content

Table 2 Baseline patient demographics and clinical characteristics of the modified full analysis set

From: Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B

Characteristic

Micafungin

Liposomal amphotericin B

Total

 

Non-ICU (n = 127)

ICU (n = 120)

Non-ICU (n = 136)

ICU (n = 110)

Non-ICU (n = 263)

ICU (n = 230)

Age (years)

      

Mean ± standard deviation

53.1 ± 16.90

52.4 ± 19.40

53.7 ± 18.74

53.4 ± 17.76

53.4 ± 17.85

52.9 ± 18.60

   Median

54.0

54.5

55.5

56.0

55.0

56.0

   Range

18.0 to 87.0

18.0 to 89.0

16.0 to 89.0

17.0 to 97.0

16.0 to 89.0

17.0 to 97.0

Male, n (%)

79 (62.2)

76 (63.3)

79 (58.1)

68 (61.8)

158 (60.1)

144 (62.6)

Female, n (%)

48 (37.8)

44 (36.7)

57 (41.9)

42 (38.2)

105 (39.9)

86 (37.4)

Race, n (%)

      

   Black

11 (8.7)

2 (1.7)

7 (5.1)

3 (2.7)

18 (6.8)

5 (2.2)

   Caucasian

84 (66.1)

65 (54.2)

97 (71.3)

56 (50.9)

181 (68.8)

121 (52.6)

   Other

32 (25.20)

53 (44.17)

32 (23.5)

51 (46.4)

64 (24.3)

104 (45.2)

Region, n (%)

      

   Brazil

37 (29.1)

18 (15.0)

42 (30.9)

15 (13.6)

79 (30.0)

33 (14.3)

   Europe

37 (29.1)

46 (38.3)

43 (31.6)

34 (30.9)

80 (30.4)

80 (34.8)

   India

12 (9.4)

44 (36.7)

20 (14.7)

39 (35.5)

32 (12.2)

83 (36.1)

   North America

11 (8.7)

6 (5.0)

12 (8.8)

7 (6.4)

23 (8.7)

13 (5.7)

   Other

30 (23.6)

6 (5.0)

19 (14.0)

15 (13.6)

49 (18.6)

21 (9.1)

APACHE II score

      

   Mean ± standard deviation

13.4 ± 6.32

18.4 ± 9.39

14.1 ± 6.60

17.8 ± 9.35

13.8 ± 6.46

18.1 ± 9.35

   Median

13.0

19.0

14.0

17.0

14.0

17.5

   Range

0 to 30.0

0 to 44.0

0 to 37.0

0 to 47.0

0 to 37.0

0 to 47.0

Relevant risk factors

      

   Catheter present

95 (75.4)

116 (96.7)

93 (68.4)

105 (95.5)

188 (71.8)

221 (96.1)

   Bone marrow transplant

4 (3.1)

2 (1.7)

2 (1.5)

1 (0.9)

6 (2.3)

3 (1.3)

   Neutropenia

26 (20.5)

6 (5.0)

21 (15.4)

4 (3.6)

47 (17.9)

10 (4.3)

   Persistent neutropenia during therapy

11 (8.8)

3 (2.5)

7 (5.3)

2 (1.9)

18 (7.0)

5 (2.2)

   Acute leukemia

20 (15.7)

1 (0.8)

13 (9.6)

3 (2.7)

33 (12.5)

4 (1.7)

   Hematological disorder

37 (29.1)

7 (5.8)

24 (17.6)

8 (7.3)

61 (23.2)

15 (6.5)

   Liver disorder/failure

1 (0.8)

0 (0.0)

2 (1.5)

0 (0.0)

3 (1.1)

0 (0.0)

   Pancreatitis

5 (3.9)

4 (3.3)

3 (2.2)

6 (5.5)

8 (3.0)

10 (4.3)

   Renal disorder/failure

0 (0.0)

2 (1.7)

1 (0.7)

0 (0.0)

1 (0.4)

2 (0.9)

   Solid organ tumor

23 (18.1)

12 (10.0)

27 (19.9)

23 (20.9)

50 (19.0)

35 (15.2)

   Solid organ transplant

4 (3.1)

9 (7.5)

5 (3.7)

4 (3.6)

9 (3.4)

13 (5.7)

Antibiotic use

23 (18.1)

29 (24.2)

28 (20.6)

35 (31.8)

51 (19.4)

64 (27.8)

   Corticosteroid therapy

14 (11.0)

22 (18.3)

20 (14.7)

17 (15.5)

34 (12.9)

39 (17.0)

   Other immunosuppression

9 (7.1)

11 (9.2)

8 (5.9)

7 (6.4)

17 (6.5)

18 (7.8)

   Intravenous line/device

40 (31.5)

26 (21.7)

35 (25.7)

20 (18.2)

75 (28.5)

46 (20.0)

Length of hospital stay

      

   Mean ± standard deviation

21.6 ± 17.77

20.0 ± 20.36

23.2 ± 20.35

27.6 ± 47.59

22.5 ± 19.13

23.6 ± 36.16

   Median

18.0

14.0

19.5

15.0

19.0

14.5

   Range

2 to 82.0

1 to 126.0

1 to 97.0

1 to 388.0

1 to 97.0

1 to 388.0

  1. APACHE, Acute Physiology and Chronic Health Evaluation; ICU, intensive care unit.